Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）

Peking University People's Hospital6 enrolled

Overview

The investigators evaluate the effectiveness and safeness of low-dose Recombinant Human Interleukin-2 （rhIL-2） for MAS.

Autoimmune-associated macrophage activation syndrome (MAS), also known as secondary hemophagocytic lymphohistiocytosis (HLH), is a rapidly progressing life-threatening disease. VP16 (Etoposide) is a well-known standard therapy, but is associated with substantial adverse effects, especially myelosuppression and infections , while steroids and ciclosporin (CSA) are not always efficient in this disease. The investigators hypothesized that low- dose IL-2 could be a novel therapy in MAS. This clinical study will test the efficacy and safety of low dose IL-2 treatment in MAS. The investigators perform a single-centre pilot trial with rhIL-2 in MAS. The investigators evaluate the effectiveness and safeness of low-dose IL-2 for MAS.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Macrophage Activation Syndrome

Interventions

Interleukin-2DRUG

Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.

Eligibility

Sex: ALLMin age: 16 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of Macrophage Activation Syndrome（MAS） * MAS secondary to autoimmune disease, such as Adult onset still's disease (AOSD), juvenile rheumatoid arthritis (JRA) or Systemic Lupus Erythematosus (SLE). Exclusion Criteria: * Primary MAS * Secondary to neoplasia, lymphoma and virus infection * pre-treatment with Cyclosporine A * relevant cardiac, pulmonary, neurologic or psychiatric disease * life-Vaccination within 4 weeks before begin with study medication * pregnant or breast-feeding * weight under 45kg or more than 80kg

Locations (1)

Department of Rheumatology and Immunology, Peking University People's Hospital

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Disease activity on the HScore (a Score for the Diagnosis of Reactive Hemophagocytic Syndrome)

Examination of the therapeutic effects (improvement in HScore) of low dose IL-2 in patients with MAS

Time frame: 1month

Central Contacts

Jing He, MD

CONTACT

8618611707347 hejing1105@126.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.